Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer
| Autor: | Zhanar Zamanbekova, Baurzhan S. Azizov, Aynur Krykpayeva, Natalya Glushkova, Zhanar Zhumanbaeva, Aray Mukanova, Maira Espenbetova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult Male Proto-Oncogene Proteins B-raf medicine.medical_specialty endocrine system diseases Proliferation index Proliferative index Population Biophysics 030218 nuclear medicine & medical imaging Papillary thyroid cancer 03 medical and health sciences BRAF Gene Mutation 0302 clinical medicine Internal medicine medicine Humans Thyroid Neoplasms education Thyroid cancer General Environmental Science education.field_of_study Radiation biology business.industry Thyroid Middle Aged medicine.disease Kazakhstan medicine.anatomical_structure Ki-67 Antigen Thyroid Cancer Papillary 030220 oncology & carcinogenesis Ki-67 Mutation biology.protein Female business |
| Zdroj: | Radiation and environmental biophysics. 60(2) |
| ISSN: | 1432-2099 |
| Popis: | In recent years, many studies were dedicated to the search for genetic markers in thyroid malignancies, including papillary thyroid cancer. This study was designed to investigate the prevalence of BRAFV600E mutation in the PTC in the Kazakh population, to evaluate the relationship between BRAF V600E mutation status and the clinicopathological features of PTC. Besides, we aimed at assessing of the relationship between the high proliferation index and the clinicopathological features of PTC and also between the concomitant coexistence of BRAFV600E and the high proliferative index with clinicopathological features of PTC. We carried out a cross-sectional study on 123 patients with PTC of Kazakh ethnicity and analyzed their clinical, laboratory, and genetic findings. The study groups were pooled based on the presence of mutated or wild-type BRAFV600E and quantitative assessment of Ki-67 marker expression. In the course of our study, we found that the age of patients from the group of BRAF gene mutation was significantly higher than that of patients from the wild-type group (48.63 ± 14.07 years versus 40.23 ± 14.34 years) (t = − 3.257; p = 0.001). Correlation analysis between BRAF mutation, Ki-67 expression, their combination and various clinical and pathological parameters in PTC patients showed that older age was positively correlated with higher frequency of mutant BRAF gene (r = 0.284; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink